

Accepted Manuscript

Abacavir and cardiovascular disease: A critical look at the data.

Josep M. Llibre, Andrew Hill

PII: S0166-3542(16)30295-9

DOI: [10.1016/j.antiviral.2016.05.015](https://doi.org/10.1016/j.antiviral.2016.05.015)

Reference: AVR 3823

To appear in: *Antiviral Research*

Received Date: 24 December 2015

Revised Date: 29 April 2016

Accepted Date: 24 May 2016

Please cite this article as: Llibre, J.M., Hill, A., Abacavir and cardiovascular disease: A critical look at the data., *Antiviral Research* (2016), doi: 10.1016/j.antiviral.2016.05.015.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Abacavir and Cardiovascular Disease: A Critical Look at the Data.

Josep M LLIBRE ¹, MD, PhD, Andrew Hill ².

¹ Infectious Diseases and “Lluita contra la SIDA” Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Universitat Autònoma de Barcelona, Barcelona, Spain

² St Stephens AIDS Centre, Chelsea and Westminster Hospital, London SW6, United Kingdom.

Keywords: Abacavir; myocardial infarction; cardiovascular risk; cohort studies.

Short title: Abacavir an myocardial infarction.

Word count: 2748 words (body). Abstract: 207 words.

Tables: 2. Figures: 0.

Corresponding author:

Josep M Llibre

Unitat de HIV, Hospital Universitari Germans Trias i Pujol, Ctra de Canyet, s/n, 08916 Badalona. Spain

Email: jllibre@flsida.org

Phone: +34 93 4978887.

Conflicts of Interest:

Josep M Llibre has served as an advisor or speaker or has been awarded with grants for clinical research from Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare, Bristol-Myers Squibb, and Janssen-Cilag.

Andrew Hill has received consultancy payments from Gilead Sciences, Cipla, ViiV Healthcare, Bristol-Myers Squibb, and Janssen-Cilag, not connected with this project.

Download English Version:

<https://daneshyari.com/en/article/5821612>

Download Persian Version:

<https://daneshyari.com/article/5821612>

[Daneshyari.com](https://daneshyari.com)